triptolide

Triptolide (PG490) belongs to the tricyclic diterpenoid group of natural products and is an inhibitor of NF-κB activation. Triptolide exhibits immunosuppressive, anti-rheumatic, anti-inflammatory, anti-proliferative and anti-tumor activities.

Triptolide-d3 is the deuterated form of Triptolide. Triptolide is a diterpene triepoxide extracted from the roots of the Thunder God Vine and is known for its immunosuppressive, anti-inflammatory, antiproliferative, and antitumor properties.

Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-triptolide is a drug-linker conjugate for ADCs (antibody-drug conjugates). It consists of Triptolide coupled with a stable, cleavable linker [Bis(vinylsulfonyl)piperazine-triazole-PEG3-O-diisopropylsilyl-Cl]. This compound is utilized in the synthesis of antibody-drug conjugates (ADCs).

Triptolide (Standard) is a reference standard for research and analysis in studies involving Triptolide. Triptolide (PG490) belongs to the tricyclic diterpenoid group of natural products and is an inhibitor of NF-κB activation. Triptolide exhibits immunosuppressive, anti-rheumatic, anti-inflammatory, anti-proliferative and anti-tumor activities.

Omtriptolide, triptolide purified from the Chinese herb, is a water-soluble derivative prodrug.

Omtriptolide sodium is a biochemical.

(5R)-5-Hydroxytriptolide, a compound extracted from Tripterygium wilfordii, exhibits lower cytotoxicity and higher immunosuppressive activity. It is useful for research in rheumatoid arthritis.

Famitinib malate (SHR1020) is an orally active multi-targeted kinase inhibitor that effectively inhibits the activity of c-kit, VEGFR-2, and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM, and 6.6 nM, respectively. It induces cell apoptosis and demonstrates potent antitumor activity in human gastric cancer cells and xenografts, making it a valuable compound for cancer research.

TP-DEA2, a prodrug of triptolide, effectively inhibits bleomycin-induced pulmonary fibrosis and inflammatory responses. It significantly reduces the production of α-SMA.

Hsp90-Cdc37-IN-4 is a novel derivative of triptolide that inhibits the protein-protein interaction (PPI) between Hsp90 and Cdc37. It selectively inhibits casein kinase 2 (CK 2), reducing the phosphorylation of its substrate Cdc37 at the serine 13 site. Additionally, Hsp90-Cdc37-IN-4 induces cell cycle arrest in the G0/G1 phase and triggers apoptosis via the mitochondrial pathway. This compound exhibits significant anti-breast cancer activity.

Antitumor agent-76 is a water-soluble, orally active, rapid-release prodrug of Triptolide that exhibits anticancer effects.

Antitumor agent-56 is an orally active triptolide derivative that significantly inhibits melanoma growth, exhibiting anti-tumour, anti-inflammatory and NO-releasing effects.

Mal-PEG-OH (MW 2000) serves as a macromolecular initiator for the ring-opening polymerization of LA to produce amphiphilic diblock copolymers. These amphiphilic block copolymers are used to prepare nanoparticles, forming an active drug delivery system. The nanoparticles can encapsulate Triptolide , addressing its poor water solubility and reducing its toxicity.

Mal-PEG-OH (MW 5000) serves as a macromolecular initiator in the ring-opening polymerization of LA to obtain an amphiphilic diblock copolymer. This copolymer is used to prepare nanoparticles, forming an active drug delivery system. The nanoparticles encapsulate Triptolide , overcoming the poor water solubility of Triptolide and reducing its toxicity.